Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Mark Gergen
|
| gptkbp:collaboratesWith |
gptkb:Roche
|
| gptkbp:focusesOn |
gptkb:gene_therapy
gptkb:CAR-T_therapies oncology genetic diseases |
| gptkbp:foundedBy |
Eric Ostertag
|
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
P-BCMA-101
P-MUC1C-ALLO1 P-PSMA-101 |
| gptkbp:numberOfEmployees |
200+
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
PSTX
|
| gptkbp:website |
https://poseida.com/
|
| gptkbp:bfsParent |
gptkb:Sorrento_Mesa
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Poseida Therapeutics
|